LY2787106

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY2787106, covering 2018-10-03 to 2018-10-03. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study of LY2787106 in Cancer and Anemia [Phase 1]